PT Mitsubishi Tanabe Pharma Indonesia (Indonesia)

Mitsubishi Tanabe Pharma Indonesia is primarily engaged in medicinals and botanicals activity. Its headquarters is located in Dki Jakarta. The company was founded in 1970. Mitsubishi Tanabe Pharma Indonesia is a subsidiary of Mitsubishi Tanabe Pharma Corporation, a leading pharmaceutical company based in Japan. The parent company was established in 2007 through the merger of Tanabe Seiyaku Co., Ltd. and Mitsubishi Pharma Corporation. Mitsubishi Tanabe Pharma Corporation is part of the Mitsubishi Chemical Holdings Group, which is one of the largest chemical companies in Japan. The primary business line of Mitsubishi Tanabe Pharma Indonesia is the development, manufacturing, and marketing of pharmaceutical products. The company focuses on therapeutic areas such as immunology, diabetes, cardiovascular, and central nervous system disorders. Some of its well-known products include Remicade, an immunosuppressive drug, and Canagliflozin, used for the treatment of type 2 diabetes. Mitsubishi Tanabe Pharma Indonesia operates several branches across Indonesia, ensuring a strong local presence and distribution network. The company is committed to expanding its footprint in the Southeast Asian market and has been actively involved in research and development to introduce innovative healthcare solutions. Globally, Mitsubishi Tanabe Pharma Corporation has a significant presence in North America, Europe, and Asia, with research facilities and partnerships that enhance its global operations. The company collaborates with various international pharmaceutical firms and research institutions to advance its product offerings and reach new markets. As a member of several pharmaceutical and healthcare associations, Mitsubishi Tanabe Pharma Indonesia is dedicated to improving healthcare standards and contributing to the well-being of society through its high-quality products and services.